Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 6/20 | 0.62 |
| ▸ | ALK | Q9UM73 | 12/20 | 0.61 |
| ▸ | INSR | P06213 | 4/20 | 0.61 |
| ▸ | IGF1R | P08069 | 3/20 | 0.61 |
| ▸ | AXL | P30530 | 1/20 | 0.60 |
| ▸ | MET | P08581 | 3/20 | 0.55 |
| ▸ | EGFR | P00533 | 2/20 | 0.54 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.50 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24716906 | 0.83 | MAP4K1 (0.76) | MAP4K1ALKINSRIGF1RMET | |
| SCHEMBL24716026 | 0.82 | AXL (0.60) | MAP4K1ALKINSRIGF1RAXL | |
| SCHEMBL24716294 | 0.82 | MAP4K1 (0.54) | MAP4K1ALKINSRIGF1RMET | |
| SCHEMBL24716911 | 0.81 | ALK (0.62) | MAP4K1ALKINSRIGF1RAXL | |
| SCHEMBL24394215 | 0.80 | MAP4K1 (0.43) | MAP4K1ALKINSRIGF1R | |
| SCHEMBL24716373 | 0.78 | ALK (0.58) | MAP4K1ALKAXL | |
| SCHEMBL29025264 | 0.78 | MAP4K1 (0.46) | MAP4K1ALK | |
| SCHEMBL20214583 | 0.77 | MAP4K1 (1.00) | MAP4K1ALKINSRIGF1RMET | |
| SCHEMBL25339375 | 0.76 | MAP4K1 (0.61) | MAP4K1ALKINSRIGF1RMET | |
| SCHEMBL30446890 | 0.76 | MAP4K1 (0.58) | MAP4K1ALKINSRIGF1RMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022214008-A1 | HIGHLY ACTIVE HPK1 KINASE INHIBITOR | 杭州阿诺生物医药科技有限公司 | 2022-10-13 | — | — | WO | disclosed |